The combination of Jun N-terminal kinase inhibitor and TNP-470 blocks carcinosarcoma-induced endothelial cell tube formation in a synergistic manner

Cancer Letters

Volumn 220, Issue 1, 2005, Pages 49-55

  Miura, Shin Ichiro ^a   Emoto, Makoto ^a   Matsuo, Yoshino ^a   Kawarabayashi, Tatsuhiko ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

FU MMT 1; Jun N terminal kinase inhibitor; Matrix metalloproteinases; TNP 470

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; VASCULOTROPIN;

ARTERY ENDOTHELIUM; ARTICLE; CARCINOSARCOMA; CELL LINE; CELL PROLIFERATION; CELL SECRETION; CONCENTRATION (PARAMETERS); ENDOTHELIUM CELL; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 14644420870     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.06.048     Document Type: Article

References (34)

1. B. Derijard, M. Hibi, I.H. Wu, T. Barrett, B. Su, and T. Deng JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain Cell 76 1994 1025 1037
2. M. Karin The regulation of AP-1 activity by mitogen-activated protein kinases J. Biol. Chem. 270 1995 16483 16486
3. B.L. Bennett, D.T. Sasaki, B.W. Murray, E.C. O'Leary, S.T. Sakata, and W. Xu SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase Proc. Natl Acad. Sci. USA 98 2001 13681 13686
4. M. Shin, C. Yan, and D. Boyd An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression Biochim. Biophys. Acta 1589 2002 311 316
5. C. Dong, D.D. Yang, M. Wysk, A.J. Whitmarsh, R.J. Davis, and R.A. Flavell Defective T cell differentiation in the absence of Jnk1 Science 282 1998 2092 2095
6. C. Tournier, P. Hess, D.D. Yang, J. Xu, T.K. Turner, and A. Nimnual Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway Science 288 2000 870 874
7. J.M. Isner, and T. Asahara Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization J. Clin. Invest. 103 1999 1231 1236
8. E.C. Griffith, Z. Su, S. Niwayama, C.A. Ramsay, Y.H. Chang, and J.O. Liu Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2 Proc. Natl Acad. Sci. USA 95 1998 15183 15188
9. D. Ingber, T. Fujita, S. Kishimoto, K. Sudo, T. Kanamaru, H. Brem, and J. Folkman Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth Nature 348 1990 555 557
10. M. Kusaka, and K. Sudo Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent Biochem. Biophys. Res. Commun. 174 1991 1070 1076
11. S. Miura, M. Emoto, Y. Matsuo, T. Kawarabayashi, and K. Saku Carcinosarcoma-induced endothelial cells tube formation through KDR/Flk-1 is blocked by TNP-470 Cancer Lett. 203 2004 45 50
12. M. Emoto, H. Iwasaki, M. Kikuchi, M. Ishiguro, T. Kubota, and H. Izumi Two cell lines established from mixed mullerian tumors of the uterus. Morphologic, immunocytochemical, and cytogenetic analyses Cancer 69 1992 1759 1768
13. M. Kusaka, K. Sudo, E. Matsutani, Y. Kozai, S. Marui, and T. Fujita Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470) Br. J. Cancer 69 1994 212 216
14. M. Emoto, H. Iwasaki, K. Oshima, M. Kikuchi, Y. Kaneko, and T. Kawarabayashi Characteristics of rhabdomyosarcoma cell lines derived from uterine carcinosarcomas Virchows Arch. 431 1997 249 256
15. S. Miura, Y. Matsuo, and K. Saku Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells Hypertension 41 2003 1118 1123
16. S. Miura, M. Fujino, Y. Matsuo, A. Kawamura, H. Tanigawa, H. Nishikawa, and K. Saku High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells Arterioscler. Thromb. Vasc. Biol. 23 2003 802 808
17. J. Vilcek, and T.H. Lee Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions J. Biol. Chem. 266 1991 7313 7316
18. K. Rutault, C.A. Hazzalin, and L.C. Mahadevan Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts J. Biol. Chem. 276 2001 6666 6674
19. C. Tournier, P. Hess, and D.D. Yang Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway Science 288 2000 870 874
20. Y. Maki, T.J. Bos, C. Davis, M. Starbuck, and P.K. Vogt Avian sarcoma virus 17 carries the jun oncogene Proc. Natl Acad. Sci. USA 84 1987 2848 2852
21. K.J. Soprano, S.C. Cosenza, G. Yumet, and D.R. Soprano Use of antisense oligomers to study the role of c-jun in G1 progression Ann. N Y Acad. Sci. 660 1992 231 239
22. F. Bost, R. McKay, M. Bost, O. Potapova, N.M. Dean, and D. Mercola The Jun kinase 2 isoform is preferentially required for epidermal growth factor-induced transformation of human A549 lung carcinoma cells Mol. Cell Biol. 19 1999 1938 1949
23. S.B. Desai, and S.K. Libutti Tumor angiogenesis and endothelial cell modulatory factors J. Immunother. 22 1999 186 211
24. H.J. Norris, and H.B. Taylor A clinical and pathologic study of 31 carcinosarcomas Cancer 19 1966 1459 1465
25. A.G. Östör, and T.P. Rollason Mixed tumours of the uterus H. Fox M. Wells fourth ed. Haines and Taylor. Obstetrical and Gynaecological Pathology vol. 1 1995 Churchill Livingstone New York, NY 606 610
26. M. Emoto, H. Iwasaki, M. Ishiguro, M. Ishiguro, M. Kikuchi, and S. Horiuchi Angiogenesis in carcinosarcomas of the uterus: differences in the microvessel density and expression of vascular endothelial growth factor between the epithelial and mesenchymal elements Hum. Pathol. 30 1999 1232 1241
27. M. Emoto, T. Udo, M. Kubota, T. Kawarabayashi, M. Ishiguro, and H. Iwasaki Neovascularization of uterine carcinosarcoma: a report of two cases analyzed by color doppler ultrasound and microvessel density J. Ultrasound Med. 18 1999 315 319
28. C. Fisher, S. Gilbertson-Beadling, E.A. Powers, G. Petzold, R. Poorman, and M.A. Mitchell Interstitial collagenase is required for angiogenesis in vitro Dev. Biol. 162 1994 499 510
29. S. Samantaray, R. Sharma, T.K. Chattopadhyaya, S.D. Gupta, and R. Ralhan Increased expression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma J. Cancer Res. Clin. Oncol. 130 2004 37 44
30. B.C. Sheu, H.C. Lien, H.N. Ho, H.H. Lin, S.N. Chow, S.C. Huang, and S.M. Hsu Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer Cancer Res. 63 2003 6537 6542
31. B.M. Kraling, D.G. Wiederschain, T. Boehm, M. Rehn, J.B. Mulliken, and M.A. Moses The role of matrix metalloproteinase activity in the maturation of human capillary endothelial cells in vitro J. Cell Sci. 112 1999 1599 1609
32. T.H. Vu, J.M. Shipley, G. Bergers, J.E. Berger, J.A. Helms, and D. Hanahan MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes Cell 93 1998 411 422
33. J.H. Woo, J.H. Lim, Y.H. Kim, S.I. Suh, D.S. Min, and J.S. Chang Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction Oncogene 2003 1 9
34. B.W. Wang, H. Chang, S. Lin, P. Kuan, and K.G. Shyu Induction of matrix metalloproteinases-14 and -2 by cyclical mechanical stretch is mediated by tumor necrosis factor-alpha in cultured human umbilical vein endothelial cells Cardiovasc. Res. 59 2003 460 469